Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

56.33
-0.6300-1.11%
Post-market: 57.180.8526+1.51%19:59 EDT
Volume:6.22M
Turnover:349.67M
Market Cap:7.89B
PE:38.19
High:58.00
Open:56.79
Low:54.89
Close:56.96
52wk High:76.76
52wk Low:9.57
Shares:140.01M
Float Shares:120.00M
Volume Ratio:2.48
T/O Rate:5.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.48
EPS(LYR):-0.0122
ROE:75.50%
ROA:14.35%
PB:13.87
PE(LYR):-4,619.86

Loading ...

BRIEF-Arrowhead Pharmaceuticals Offers 3,100,776 Shares At $64.50 Per Share

Reuters
·
Jan 08

Arrowhead Pharmaceuticals - Offers 3,100,776 Shares at $64.50 per Share

THOMSON REUTERS
·
Jan 08

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's

Reuters
·
Jan 08

BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine Foods

Reuters
·
Jan 07

Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $80 From $60, Maintains Buy Rating

MT Newswires Live
·
Jan 07

Arrowhead Pharmaceuticals Shares Down 3.4% Premarket After Co Announces Stock Sale, Convertible Bond Offering

THOMSON REUTERS
·
Jan 07

Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jan 07

BRIEF-Arrowhead Pharmaceuticals Announces Nmpa Approval Of Redemplo® (Plozasiran)

Reuters
·
Jan 07

China Approves Arrowhead’s REDEMPLO for Familial Chylomicronemia Syndrome

Reuters
·
Jan 07

Arrowhead Pharmaceuticals: Nmpa Approval Triggers $10 Mln Milestone Payment to Be Paid by Sanofi to Arrowhead Subsidiary Visirna Therapeutics

THOMSON REUTERS
·
Jan 07

Arrowhead Pharmaceuticals Announces Nmpa Approval of Redemplo® (Plozasiran) for Familial Chylomicronemia Syndrome (Fcs) in China

THOMSON REUTERS
·
Jan 07

Arrowhead Pharmaceuticals : Leerink Partners Raises Target Price to $60 From $44

THOMSON REUTERS
·
Jan 07

U.S. RESEARCH ROUNDUP-Alphabet, Hershey, Micron Technology

Reuters
·
Jan 07

Arrowhead Pharmaceuticals : Chardan Capital Markets Raises Target Price to $80 From $60

THOMSON REUTERS
·
Jan 07

Arrowhead Pharmaceuticals Announces $500 Million Convertible Senior Notes and $200 Million Stock Offerings

Reuters
·
Jan 07

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

THOMSON REUTERS
·
Jan 07

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay. -- Barrons.com

Dow Jones
·
Jan 07

Arrowhead Pharma Shares up 15.7% After Early Trial Data Shows Rnai Obesity Drugs Helped Obese Patients With Diabetes Lose Weight

THOMSON REUTERS
·
Jan 06

Arrowhead Shares Jump 15% as Its Gene-Silencing Drugs Cut Fat in Early Obesity Studies

Tiger Newspress
·
Jan 06

Arrowhead Pharmaceuticals Reports Promising Interim Results for RNAi-Based Obesity Therapies in Phase 1/2a Trials

Reuters
·
Jan 06